By Ivana Magovčević-Liebisch, CEO of Vigil Neuroscience, as part of the From The Trenches feature of LifeSciVC Over my many years in the biopharma industry, working across disease areas, including orphan indications, I have learned that to impact patients’ lives

There’s “just too many early stage companies going public”, or so goes one of the most common lamentations about the current state of the biotech market. I’ve read a good deal of venting covering this theme, including comments about VCs

Misery loves company, and so it goes with the stock market for the innovation ecosystem these days. The general risk-off market environment has been crushing both the emerging tech and biotech sectors alike. Last year, generalists in many ways capitulated

Biotech sentiment is super bearish today, as the sector has been crushed over the last year. There’s blood in the water, especially for small and mid-cap players, and everyone’s looking for what caused the carnage. There are many factors at

By Bob Clarke, CEO of Kinaset Therapeutics, as part of the From The Trenches feature of LifeSciVC. In December 2019, I was in London meeting with my future co-founders to discuss an asset that would eventually become the cornerstone of

By Jonathan Montagu, CEO of HotSpot Therapeutics, and Ramy Farid, CEO of Schrodinger, as part of the From The Trenches feature of LifeSciVC. No, your next doctor will not be a robot. Nor will an algorithm cure cancer. However, AI

By Deanna M. Petersen, CBO of AVROBIO, as part of the From The Trenches feature of LifeSciVC One of the most common questions I get asked is how I got into the business side of the biotech industry, and in

By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC For anyone that’s part of a fast paced, growing organization, resilience is the key to thriving.  It supports our audacity, ability to tune

By Rene Russo, CEO of Xilio Therapeutics, as part of the From The Trenches features of LifeSciVC When your team’s priority is to execute a well-formed plan, then a “heads down” focus is critical. We all recognize this situation, using

By Aoife Brennan, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC. From the first time I heard the story of the American chestnut, I was fascinated. It is a story with threads from history, ecology,

By Sush Patel, CCO of Replimune as part of the From The Trenches feature of LifeSciVC. After close to 20 years at Genentech (GNE) shaping and directing marketing and commercialization efforts for novel oncology therapies, I finally took the plunge

By Jonathan Montagu, CEO and Co-founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC Today marks an important point in our journey to patients as HotSpot Therapeutics announces its $100MM Series C financing.  This infusion